Healthcare / Pharmaceutical RetailersXETRA
$46.90
+0.76 (+1.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-20.0M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$957M
P/E
N/A
•EV/EBITDA
26.3x
↑ROE
-8.2%
↓Gross Margin
22.5%
↓Debt/Equity
0.91
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.7%
FCF CAGR
—
FCF margin
-3.0%
FCF / Net income
2.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.94B · net income $-37.7M · FCF $-87.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.94B | $2.94B | $2.37B | $1.80B | $1.20B |
| Net Income | $-37.7M | $-37.7M | $-45.5M | $-12.0M | $-77.6M |
| EBITDA | $48.1M | $48.1M | $28.1M | $50.9M | $-36.1M |
| EPS | -1.87 | -1.87 | -2.27 | -0.73 | -4.32 |
| Gross Margin | 22.5% | 22.5% | 23.0% | 24.5% | 27.5% |
| Operating Margin | -1.0% | -1.0% | -1.6% | -1.0% | -5.8% |
| Net Margin | -1.3% | -1.3% | -1.9% | -0.7% | -6.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.91 | 0.91 | 0.51 | 0.47 | 0.72 |
| Current Ratio | 1.54 | 1.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-87.6M | $-87.6M | $-20.0M | $23.2M | $-82.6M |
| Returns | |||||
| ROE | -8.2% | -8.2% | -9.4% | -2.3% | -21.9% |
| Valuation | |||||
| EV/EBITDA | 26.33 | 26.33 | 94.97 | 54.90 | — |
| P/B | 2.05 | 2.05 | 5.20 | 5.05 | 2.57 |
| Growth & Yield | |||||
| Revenue Growth | 24.1% | 24.1% | 31.8% | 49.4% | — |
| EPS Growth | 17.6% | 17.6% | -211.0% | 83.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.27 → -1.87
Residual
-53.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.